Nanoparticle-neutrophils interactions for autoimmune regulation

• Published in: Advanced drug delivery reviews 2024-06, Vol.209, p.115316, Article 115316
• Main Authors: Kupor, Daniel, Felder, Michael L., Kodikalla, Shivanie, Chu, Xueqi, Eniola-Adefeso, Omolola
• Format: Article
• Language: English
• Subjects: Animals; Autoimmune disease; Autoimmune Diseases - drug therapy; Autoimmune Diseases - immunology; Autoimmunity; Controlled release; Drug delivery; Drug Delivery Systems; Humans; Immune response; Inflammation; Nanoparticles; Neutrophils; Neutrophils - immunology; Targeting
• ISSN: 0169-409X; 1872-8294; 1872-8294
• DOI: 10.1016/j.addr.2024.115316

[Display omitted] Neutrophils play an essential role as ‘first responders’ in the immune response, necessitating many immune-modulating capabilities. Chronic, unresolved inflammation is heavily implicated in the progression and tissue-degrading effects of autoimmune disease. Neutrophils modulate disease pathogenesis by interacting with the inflammatory and autoreactive cells through effector functions, including signaling, degranulation, and neutrophil extracellular traps (NETs) release. Since the current gold standard systemic glucocorticoid administration has many drawbacks and side effects, targeting neutrophils in autoimmunity provides a new approach to developing therapeutics. Nanoparticles enable targeting of specific cell types and controlled release of a loaded drug cargo. Thus, leveraging nanoparticle properties and interactions with neutrophils provides an exciting new direction toward novel therapies for autoimmune diseases. Additionally, recent work has utilized neutrophil properties to design novel targeted particles for delivery into previously inaccessible areas. Here, we outline nanoparticle-based strategies to modulate neutrophil activity in autoimmunity, including various nanoparticle formulations and neutrophil-derived targeting.